Illumina Ventures
Venture Capital
Active
San Francisco, United States
66
47M
37
8.25
12
0.44
2
- Areas of investment
Summary
Illumina Ventures is the famous VC, which was founded in 2016. The company was established in North America in United States. Illumina Ventures appeared to be a CVC structure as part of the corporation. The main department of described VC is located in the Foster City.
Among the most popular portfolio startups of the fund, we may highlight 23andMe, Human Longevity, DNA Script. The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Health Diagnostics, Genetics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
This organization was formed by Nicholas J. Naclerio. The overall number of key employees were 4.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Illumina Ventures, startups are often financed by Polaris Partners, NanoDimension, Alexandria Venture Investments. The meaningful sponsors for the fund in investment in the same round are Polaris Partners, Alexandria Venture Investments, ARCH Venture Partners. In the next rounds fund is usually obtained by Euclidean Capital, Bpifrance, Two Sigma Ventures.
Comparing to the other companies, this Illumina Ventures performs on 23 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2018. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 24 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Illumina Ventures is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
- Check size
- 500K — 10M
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 325000000
- Fund raised date
- 2021-09-29
Analytics
- Total investments
- 66
- Lead investments
- 12
- Exits
- 2
- Rounds per year
- 8.25
- Follow on index
- 0.44
- Investments by industry
- Biotechnology (56)
- Health Care (38)
- Medical (25)
- Genetics (18)
- Life Science (18) Show 26 more
- Investments by region
-
- United States (55)
- France (8)
- United Kingdom (3)
- Peak activity year
- 2020
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 192M
- Group Appearance index
- 0.92
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Entos | 18 Jun 2024 | Software, Artificial Intelligence, Machine Learning | Early Stage Venture | 50M | United States, California, Los Angeles |
| Pluton Biosciences | 24 May 2023 | Biotechnology, AgTech | Early Stage Venture | 16M | United States, Missouri, Saint Louis |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.